TY - JOUR AU - Jaya Sharma AU - John Ng AU - Martin Goodman AU - Muhammad Saif PY - 2013/03/10 Y2 - 2024/03/28 TI - New Developments in the Management of Borderline Resectable Pancreatic Cancer JF - JOP. Journal of the Pancreas JA - JOP VL - 14 IS - 2 SE - Highlights from the “2013 ASCO Gastrointestinal Cancers Symposium”. San Francisco, CA, USA. January 24-26, 2013 DO - 10.6092/1590-8577/1473 UR - http://www.serena.unina.it/index.php/jop/article/view/1473 AB - The optimal management of borderline resectable pancreatic cancer remains unclear. Neoadjuvant chemoradiation remains the most common approach in the United States, while neoadjuvant chemotherapy alone is also widely utilized and has demonstrated efficacy but there has been no clear consensus about a regimen that would be most beneficial in this setting. We will discuss three abstracts that were presented in the 2013 ASCO Gastrointestinal Cancers Symposium in which various regimens were evaluated in the neoadjuvant setting.Image: New sign at the entrance of Tufts Medical Center on the day of its renaming (March 4, 2008). (Wikimedia Commons) ER -